Log in

NASDAQ:BCRXBioCryst Pharmaceuticals Stock Price, Forecast & News

-0.30 (-6.52 %)
(As of 08/14/2020 04:00 PM ET)
Today's Range
Now: $4.30
50-Day Range
MA: $4.66
52-Week Range
Now: $4.30
Volume7.22 million shs
Average Volume8.06 million shs
Market Capitalization$759.23 million
P/E RatioN/A
Dividend YieldN/A
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma. It is also developing BCX7353, an oral serine protease inhibitor and oral dose formulation that is in Phase III clinical trials to treat hereditary angioedema; BCX9930, an oral factor D inhibitor, which is in Phase I clinical trials for mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors that is in preclinical trials to treat fibrodysplasia ossificans progressive; and Galidesivir, an RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trials to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Read More
BioCryst Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.31 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:BCRX



Sales & Book Value

Annual Sales$48.83 million
Book Value$0.26 per share


Net Income$-108,900,000.00
Net Margins-236.65%
Return on Equity-53,981.51%


Market Cap$759.23 million
Next Earnings Date11/4/2020 (Estimated)
-0.30 (-6.52 %)
(As of 08/14/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BCRX News and Ratings via Email

Sign-up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

BioCryst Pharmaceuticals (NASDAQ:BCRX) Frequently Asked Questions

How has BioCryst Pharmaceuticals' stock price been impacted by Coronavirus?

BioCryst Pharmaceuticals' stock was trading at $2.59 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BCRX stock has increased by 66.0% and is now trading at $4.30.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of BioCryst Pharmaceuticals?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioCryst Pharmaceuticals in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for BioCryst Pharmaceuticals

When is BioCryst Pharmaceuticals' next earnings date?

BioCryst Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for BioCryst Pharmaceuticals

How were BioCryst Pharmaceuticals' earnings last quarter?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced its earnings results on Thursday, August, 6th. The biotechnology company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.04. The biotechnology company earned $2.87 million during the quarter, compared to analysts' expectations of $3.17 million. BioCryst Pharmaceuticals had a negative return on equity of 53,981.51% and a negative net margin of 236.65%.
View BioCryst Pharmaceuticals' earnings history

What price target have analysts set for BCRX?

8 Wall Street analysts have issued 1 year price objectives for BioCryst Pharmaceuticals' stock. Their forecasts range from $4.00 to $13.00. On average, they anticipate BioCryst Pharmaceuticals' stock price to reach $8.33 in the next twelve months. This suggests a possible upside of 93.8% from the stock's current price.
View analysts' price targets for BioCryst Pharmaceuticals

Has BioCryst Pharmaceuticals been receiving favorable news coverage?

Media stories about BCRX stock have trended negative this week, according to InfoTrie Sentiment. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. BioCryst Pharmaceuticals earned a news sentiment score of -2.7 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term.
View the latest news about BioCryst Pharmaceuticals

Are investors shorting BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals saw a increase in short interest in June. As of June 30th, there was short interest totaling 32,100,000 shares, an increase of 55.6% from the June 15th total of 20,630,000 shares. Based on an average daily volume of 11,250,000 shares, the days-to-cover ratio is presently 2.9 days.
View BioCryst Pharmaceuticals' Short Interest

Who are some of BioCryst Pharmaceuticals' key competitors?

What other stocks do shareholders of BioCryst Pharmaceuticals own?

Who are BioCryst Pharmaceuticals' key executives?

BioCryst Pharmaceuticals' management team includes the following people:
  • Mr. Jon P. Stonehouse, CEO, Pres & Director (Age 58)
  • Mr. Thomas R. Staab II, CFO, Principal Accounting Officer, Sr. VP & Treasurer (Age 51)
  • Dr. William P. Sheridan, Chief Medical Officer & Sr. VP (Age 64)
  • Dr. Yarlagadda S. Babu, Sr. VP of Drug Discovery (Age 66)
  • Ms. Lynne M. Powell, Chief Commercial Officer & Sr. VP (Age 52)

What is BioCryst Pharmaceuticals' stock symbol?

BioCryst Pharmaceuticals trades on the NASDAQ under the ticker symbol "BCRX."

Who are BioCryst Pharmaceuticals' major shareholders?

BioCryst Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (6.16%), Deerfield Management Company L.P. Series C (2.52%), Goldman Sachs Group Inc. (1.26%), Stifel Financial Corp (1.16%), Oracle Investment Management Inc. (1.13%) and Bank of America Corp DE (1.01%). Company insiders that own BioCryst Pharmaceuticals stock include Alane P Barnes, Anthony Doyle, Jon P Stonehouse, Kenneth B Lee Jr, Lynne Powell, Megan Sniecinski, Steve Aselage, Thomas R Staab II and William P Sheridan.
View institutional ownership trends for BioCryst Pharmaceuticals

Which major investors are selling BioCryst Pharmaceuticals stock?

BCRX stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Point72 Asset Management L.P., Spark Investment Management LLC, Platinum Investment Management Ltd., Deerfield Management Company L.P. Series C, Stifel Financial Corp, Virtus ETF Advisers LLC, and Marshall Wace LLP.
View insider buying and selling activity for BioCryst Pharmaceuticals

Which major investors are buying BioCryst Pharmaceuticals stock?

BCRX stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Oracle Investment Management Inc., Marshall Wace North America L.P., Bank of America Corp DE, SG Americas Securities LLC, Goldman Sachs Group Inc., Formidable Asset Management LLC, and EAM Investors LLC. Company insiders that have bought BioCryst Pharmaceuticals stock in the last two years include Alane P Barnes, Anthony Doyle, Jon P Stonehouse, Kenneth B Lee Jr, Megan Sniecinski, and Steve Aselage.
View insider buying and selling activity for BioCryst Pharmaceuticals

How do I buy shares of BioCryst Pharmaceuticals?

Shares of BCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BioCryst Pharmaceuticals' stock price today?

One share of BCRX stock can currently be purchased for approximately $4.30.

How big of a company is BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals has a market capitalization of $759.23 million and generates $48.83 million in revenue each year. The biotechnology company earns $-108,900,000.00 in net income (profit) each year or ($0.94) on an earnings per share basis. BioCryst Pharmaceuticals employs 100 workers across the globe.

What is BioCryst Pharmaceuticals' official website?

The official website for BioCryst Pharmaceuticals is www.biocryst.com.

How can I contact BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals' mailing address is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. The biotechnology company can be reached via phone at 919-859-1302 or via email at [email protected]

This page was last updated on 8/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.